Concepedia

Kaiko Kunii

KK

22

Publications

4.7K

Citations

20

H-Index

1999

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Tsukuba

Agios Pharmaceuticals (United States)

Ribon Therapeutics (United States)

Harvard University

Kaiko Kunii is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, tumor biology, and cell biology.

ORCID

Top concepts

Publications per year

1999–2022

22

Publications

22

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

Dan Rohle, Janeta Popovici-Müller, Nicolaos Palaskas et al. · Science · 2013 · 1.1K citations · Full text

, , +16

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

Dimitrios Anastasiou, Yimin Yu, William J. Israelsen et al. · Nature Chemical Biology · 2012 · 804 citations · Full text

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

Rachel Darman, Michael Seiler, Anant A. Agrawal et al. · Cell Reports · 2015 · 453 citations · Full text

, , +17

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis

Katya Marjon, Michael J. Cameron, Phong Quang et al. · Cell Reports · 2016 · 415 citations · Full text

<i>FGFR2</i> -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

Kaiko Kunii, Lenora J. Davis, Julie Gorenstein et al. · Cancer Research · 2008 · 264 citations

Rows per page

1–5 of 22